Fulcrum Therapeutics (FULC) – Investment Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Fulcrum Therapeutics (NASDAQ: FULC):

• 9/13/2024 – Fulcrum Therapeutics was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. They now have a $4.00 price target on the stock, down previously from $17.00.
• 9/12/2024 – Fulcrum Therapeutics was downgraded by analysts at Bank of America Co. from a “neutral” rating to an “underperform” rating. They now have a $2.00 price target on the stock, down previously from $10.00.
• 9/12/2024 – Fulcrum Therapeutics was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating. They now have a $4.00 price target on the stock, down previously from $15.00.
• 9/12/2024 – Fulcrum Therapeutics was downgraded by analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating.
• 9/12/2024 – Fulcrum Therapeutics had its “market perform” rating reaffirmed by analysts at Leerink Partners. They now have a $4.00 price target on the stock.
• 9/12/2024 – Fulcrum Therapeutics was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 9/12/2024 – Fulcrum Therapeutics was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $3.00 price target on the stock, down previously from $22.00.
• 9/9/2024 – Fulcrum Therapeutics was upgraded by analysts at Bank of America Co. from an “underperform” rating to a “neutral” rating. They now have a $10.00 price target on the stock, up previously from $5.00.
• 8/1/2024 – Fulcrum Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.

Fulcrum Therapeutics Stock Performance

NASDAQ FULC opened at $3.49 on Wednesday. The business’s fifty day moving average is $8.29 and its 200 day moving average is $8.16. Fulcrum Therapeutics, Inc. has a fifty-two week low of $2.87 and a fifty-two week high of $13.70. The company has a market capitalization of $216.92 million, a PE ratio of -2.18 and a beta of 2.23.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.93. The company had revenue of $80.00 million during the quarter, compared to the consensus estimate of $80.00 million. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. During the same period in the previous year, the company posted ($0.38) EPS. On average, sell-side analysts forecast that Fulcrum Therapeutics, Inc. will post -0.48 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. National Bank of Canada FI lifted its position in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after acquiring an additional 4,000 shares in the last quarter. Capstone Investment Advisors LLC bought a new stake in Fulcrum Therapeutics during the 4th quarter valued at approximately $68,000. Profund Advisors LLC purchased a new position in Fulcrum Therapeutics in the 2nd quarter worth approximately $68,000. Renaissance Technologies LLC bought a new position in Fulcrum Therapeutics in the 2nd quarter worth approximately $82,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Fulcrum Therapeutics by 66.7% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company’s stock valued at $112,000 after buying an additional 4,766 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.